Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**SSP-004184 + simvastatin** is a combination of two agents: SSP-004184 (also known as SPD602 or FBS0701), an investigational oral iron chelator developed primarily for the treatment of transfusional iron overload, and simvastatin, a statin-class small molecule approved to lower LDL cholesterol and reduce cardiovascular risk. SSP-004184 works by binding excess iron, facilitating its excretion, and potentially reducing tissue iron accumulation, which is particularly relevant in patients with chronic transfusional requirements. Simvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme of the mevalonate pathway of cholesterol biosynthesis, decreasing cholesterol production in the liver and reducing the risk of atherosclerotic cardiovascular disease. Combination use may be evaluated for pharmacokinetic interactions or safety in special populations but is not an approved or widely registered therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SSP-004184 + simvastatin.